AU774799B2 - Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy - Google Patents

Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy Download PDF

Info

Publication number
AU774799B2
AU774799B2 AU41434/00A AU4143400A AU774799B2 AU 774799 B2 AU774799 B2 AU 774799B2 AU 41434/00 A AU41434/00 A AU 41434/00A AU 4143400 A AU4143400 A AU 4143400A AU 774799 B2 AU774799 B2 AU 774799B2
Authority
AU
Australia
Prior art keywords
compound
group
angiotensin
antagonistic activity
retinopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU41434/00A
Other languages
English (en)
Other versions
AU4143400A (en
Inventor
Hitoshi Ikeda
Yasutaka Nagisa
Shizue Nakagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU4143400A publication Critical patent/AU4143400A/en
Application granted granted Critical
Publication of AU774799B2 publication Critical patent/AU774799B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request to Amend Deed and Register Assignors: TAKEDA CHEMICAL INDUSTRIES LTD.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU41434/00A 1999-04-28 2000-04-27 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy Ceased AU774799B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12149899 1999-04-28
JP11-121498 1999-04-28
PCT/JP2000/002766 WO2000066161A1 (en) 1999-04-28 2000-04-27 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy

Publications (2)

Publication Number Publication Date
AU4143400A AU4143400A (en) 2000-11-17
AU774799B2 true AU774799B2 (en) 2004-07-08

Family

ID=14812676

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41434/00A Ceased AU774799B2 (en) 1999-04-28 2000-04-27 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy

Country Status (23)

Country Link
US (2) US7064141B1 (enExample)
EP (1) EP1197223B1 (enExample)
KR (1) KR100865059B1 (enExample)
CN (1) CN1172719C (enExample)
AT (1) ATE289204T1 (enExample)
AU (1) AU774799B2 (enExample)
BR (1) BR0010084A (enExample)
CA (1) CA2371554C (enExample)
CZ (1) CZ301913B6 (enExample)
DE (1) DE60018186T2 (enExample)
DK (1) DK1197223T3 (enExample)
ES (1) ES2233362T3 (enExample)
HU (1) HU226948B1 (enExample)
MX (1) MXPA01010923A (enExample)
NO (1) NO327446B1 (enExample)
NZ (1) NZ514855A (enExample)
PL (1) PL196895B1 (enExample)
PT (1) PT1197223E (enExample)
RU (1) RU2239454C2 (enExample)
SI (1) SI1197223T1 (enExample)
SK (1) SK286859B6 (enExample)
WO (1) WO2000066161A1 (enExample)
ZA (1) ZA200108527B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
TW200304812A (en) * 2002-03-08 2003-10-16 Sankyo Co An eye drop containing a tetrazole derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
ES2535291T3 (es) * 2003-04-15 2015-05-08 Daiichi Sankyo Company, Limited Medoxomilo de olmesartán para prevención o tratamiento de enfermedades oculares angiogénicas
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
ES2425750T3 (es) 2004-08-31 2013-10-17 Newsouth Innovations Pty Limited Inhibición del VEGF
PL1814527T5 (pl) * 2004-11-05 2021-08-02 Boehringer Ingelheim International Gmbh Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę
RU2420280C2 (ru) * 2005-04-21 2011-06-10 Сантен Фармасьютикал Ко., Лтд Терапевтическое средство против кератоконъюнктивального расстройства
KR20080074128A (ko) * 2005-12-06 2008-08-12 산텐 세이야꾸 가부시키가이샤 각결막 장애 치료제
TWI415634B (zh) * 2007-03-28 2013-11-21 Takeda Pharmaceutical 固態醫藥組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027211D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
DE4201554A1 (de) * 1992-01-22 1993-07-29 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
GB9223860D0 (en) * 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH0789957A (ja) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
US5889020A (en) * 1994-02-08 1999-03-30 Ciba Vision Corporation Treatment of normotensive glaucoma with angiotensin II antagonists
JPH09210183A (ja) * 1996-01-31 1997-08-12 Suzuki Motor Corp 動力伝達装置
UA49880C2 (uk) * 1996-03-29 2002-10-15 Смітклайн Бічам Корпорейшн Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі
NZ330774A (en) * 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
TW416953B (en) * 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JP4475685B2 (ja) * 1997-06-27 2010-06-09 スミスクライン・ビーチャム・コーポレイション エプロサルタン・一水和物
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
ATE341325T1 (de) * 1997-08-06 2006-10-15 Smithkline Beecham Corp Eprosartan arginyl-ladungsneutralisationskomplex und verfahren zu dessen herstellung und verabreichung
WO1999044590A1 (en) 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
KR20040078140A (ko) * 1998-07-10 2004-09-08 노파르티스 아게 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
FR2783422A1 (fr) 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
JP2000159671A (ja) 1998-12-01 2000-06-13 Takeda Chem Ind Ltd 血管新生阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REFERNCES CITED IN WO 2000/006161 *

Also Published As

Publication number Publication date
ES2233362T3 (es) 2005-06-16
WO2000066161A1 (en) 2000-11-09
US20060189669A1 (en) 2006-08-24
SI1197223T1 (enExample) 2005-08-31
NO20015257L (no) 2001-10-26
PL350554A1 (en) 2002-12-16
PL196895B1 (pl) 2008-02-29
ZA200108527B (en) 2002-10-17
HU226948B1 (en) 2010-03-29
CN1172719C (zh) 2004-10-27
BR0010084A (pt) 2002-01-15
EP1197223A1 (en) 2002-04-17
CA2371554A1 (en) 2000-11-09
DE60018186D1 (de) 2005-03-24
EP1197223B1 (en) 2005-02-16
SK15452001A3 (sk) 2002-04-04
SK286859B6 (sk) 2009-06-05
US7064141B1 (en) 2006-06-20
CA2371554C (en) 2009-06-09
ATE289204T1 (de) 2005-03-15
RU2239454C2 (ru) 2004-11-10
DE60018186T2 (de) 2005-12-29
NO327446B1 (no) 2009-06-29
AU4143400A (en) 2000-11-17
HUP0200890A3 (en) 2002-12-28
NZ514855A (en) 2004-01-30
DK1197223T3 (da) 2005-05-30
CZ301913B6 (cs) 2010-07-28
NO20015257D0 (no) 2001-10-26
CZ20013804A3 (cs) 2002-04-17
HUP0200890A2 (hu) 2002-11-28
KR100865059B1 (ko) 2008-10-23
KR20020015315A (ko) 2002-02-27
PT1197223E (pt) 2005-04-29
MXPA01010923A (es) 2002-06-21
CN1348385A (zh) 2002-05-08
EP1197223A4 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
US20100120800A1 (en) Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
EP1197223B1 (en) Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
JPWO1999059634A1 (ja) 抗炎症点眼剤
EP0771563B1 (en) Use of 5-HT1A receptor ligands for the treatment of glaucoma
US5639773A (en) Ocular hypotensive agent
JP4276768B2 (ja) 単純網膜症・前増殖網膜症の予防・治療・進展抑制剤
JPH0867674A (ja) 眼圧降下剤
JP2002212101A (ja) 歯肉肥厚抑制剤
JPWO2005079792A1 (ja) 重症糖尿病網膜症の予防又は治療剤
WO2004091659A1 (ja) 眼内血管新生性疾患の予防又は治療のための医薬
EP1579872B1 (en) Body weight gain inhibitor
JPWO2000066161A1 (ja) 単純網膜症・前増殖網膜症の予防・治療・進展抑制剤
KR20030007575A (ko) 안압 강하제

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)